메뉴 건너뛰기




Volumn 13, Issue 2, 2011, Pages 112-119

Sipuleucel-T: Prototype for development of anti-tumor vaccines

Author keywords

Dendritic cell vaccine; Immunotherapy; PAP GM CSF fusion protein; Prostate cancer; Vaccines

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BEVACIZUMAB; CALCITRIOL; CANCER ANTIBODY; CYTOTOXIC AGENT; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROVENGE; SATRAPLATIN;

EID: 79955814192     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0152-5     Document Type: Review
Times cited : (26)

References (36)
  • 1
    • 77957766128 scopus 로고    scopus 로고
    • A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
    • abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients
    • O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 2010, 28:18s: abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients.
    • (2010) J Clin Oncol , vol.28
    • O'Day, S.1    Hodi, F.S.2    McDermott, D.F.3
  • 3
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    • This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell-specific activity to P2024 and PAP. This has the most definitive dataset
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM 2010, 5:411-22. This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell-specific activity to P2024 and PAP. This has the most definitive dataset.
    • (2010) NEJM , vol.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 5
    • 68549135290 scopus 로고    scopus 로고
    • Integrated Data from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy with Sipuleucel-T in Advanced Prostate Cancer
    • This paper aggregates the data from two phase 3 trials with sipuleucel-T
    • Higano CS, Schellhammer PF, Small EJ, Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Cancer 2009,115(16):3670-79. This paper aggregates the data from two phase 3 trials with sipuleucel-T.
    • (2009) Cancer , vol.115 , Issue.16 , pp. 3670-3679
    • Higano, C.S.1    Schellhammer, P.F.2    Small, E.J.3
  • 7
    • 77952238610 scopus 로고    scopus 로고
    • Update: Immunological Strategies for Prostate Cancer
    • This is a recent review of prostate cancer immunotherapy
    • Drake CG, Antonarakis ES. Update: Immunological Strategies for Prostate Cancer. Curr Urol Rep 2010, 11:202-07. This is a recent review of prostate cancer immunotherapy.
    • (2010) Curr Urol Rep , vol.11 , pp. 202-207
    • Drake, C.G.1    Antonarakis, E.S.2
  • 9
    • 70450162100 scopus 로고    scopus 로고
    • A changing world for DCvax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer
    • Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009, 9(12):1565-75.
    • (2009) Expert Opin Biol Ther , vol.9 , Issue.12 , pp. 1565-1575
    • Fishman, M.1
  • 10
    • 3042701410 scopus 로고    scopus 로고
    • Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer
    • Zhang H, Melamed J, Wei P et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immunity 2003.3:2
    • (2003) Cancer Immunity , vol.3 , pp. 2
    • Zhang, H.1    Melamed, J.2    Wei, P.3
  • 11
    • 0028939302 scopus 로고
    • Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer
    • Sanda MG, Restifo NP, Walsh JC et al. Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. J Natl Cancer Inst 1995; 87(4):280-85.
    • (1995) J Natl Cancer Inst , vol.87 , Issue.4 , pp. 280-285
    • Sanda, M.G.1    Restifo, N.P.2    Walsh, J.C.3
  • 12
    • 70349561448 scopus 로고    scopus 로고
    • PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
    • Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114(8): 1545-52.
    • (2009) Blood , vol.114 , Issue.8 , pp. 1545-1552
    • Zhang, L.1    Gajewski, T.F.2    Kline, J.3
  • 13
    • 70349569569 scopus 로고    scopus 로고
    • Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    • Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114 (8):1537-44.
    • (2009) Blood , vol.114 , Issue.8 , pp. 1537-1544
    • Ahmadzadeh, M.1    Johnson, L.A.2    Heemskerk, B.3
  • 15
    • 36348989162 scopus 로고    scopus 로고
    • Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
    • Nefedova Y, Fishman M, Sherman S, el al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67(22):11021-8.
    • (2007) Cancer Res. , vol.67 , Issue.22 , pp. 11021-11028
    • Nefedova, Y.1    Fishman, M.2    Sherman, S.3
  • 16
    • 63849112500 scopus 로고    scopus 로고
    • The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology
    • Curti A, Trabanelli S, Salvestrini V, et al. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11): 2394-2401.
    • (2009) Blood , vol.113 , Issue.11 , pp. 2394-2401
    • Curti, A.1    Trabanelli, S.2    Salvestrini, V.3
  • 17
    • 33745559710 scopus 로고    scopus 로고
    • The role of nitric oxide in tumour progression
    • DOI 10.1038/nrc1910, PII N1910
    • Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006, 6:521-534. (Pubitemid 43980541)
    • (2006) Nature Reviews Cancer , vol.6 , Issue.7 , pp. 521-534
    • Fukumura, D.1    Kashiwagi, S.2    Jain, R.K.3
  • 18
    • 66149142809 scopus 로고    scopus 로고
    • Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis
    • Lahdenranta J, Hagendoorn J, Padera TP et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009, 69(7):2801-8.
    • (2009) Cancer Res , vol.69 , Issue.7 , pp. 2801-2808
    • Lahdenranta, J.1    Hagendoorn, J.2    Padera, T.P.3
  • 20
    • 79955823162 scopus 로고    scopus 로고
    • Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer
    • abstract #4552 Presented at This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival
    • Stewart FP, DelaRosa CP, Sheikh N et al. Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer. abstract #4552 Presented at ASCO Annual Meeting 2010 Chicago, Illinois; June 4-8, 2010. This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival.
    • ASCO Annual Meeting 2010 Chicago, Illinois; June 4-8, 2010
    • Stewart, F.P.1    DelaRosa, C.P.2    Sheikh, N.3
  • 22
    • 38349167518 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
    • Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5.
    • (2008) J Clin Oncol , vol.26 , Issue.2 , pp. 242-245
    • Berthold, D.R.1    Pond, G.R.2    Soban, F.3
  • 25
    • 73949098659 scopus 로고    scopus 로고
    • Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients with Castrate-Refractory Prostate Cancer Progressing after Prior Chemotherapy: The SPARC Trial
    • Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment
    • Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. J Clin Oncol 2009; 27(32): 5431-5438. Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment.
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5431-5438
    • Sternberg, C.N.1    Petrylak, D.P.2    Sartor, O.3
  • 26
    • 77955714649 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401
    • abstract LBA4511
    • Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401. J Clin Oncol 2010; 28:18s. abstract LBA4511.
    • (2010) J Clin Oncol , vol.28
    • Kelly, W.K.1    Halabi, S.2    Carducci, M.A.3
  • 28
    • 79955068371 scopus 로고    scopus 로고
    • Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial
    • abstract # 4509
    • Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial. J Clin Oncol 2010; 28:15s:abstract # 4509.
    • (2010) J Clin Oncol , vol.28
    • Scher, H.I.1    Chi, K.N.2    De Wit, R.3
  • 29
    • 0034554863 scopus 로고    scopus 로고
    • Immunotherapy of Hormone-Refractory Prostate Cancer with Antigen-Loaded Dendritic Cells
    • Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J Clin Oncol 2000;18(23):3894-3903.
    • (2000) J Clin Oncol , vol.18 , Issue.23 , pp. 3894-3903
    • Small, E.J.1    Fratesi, P.2    Reese, D.M.3
  • 30
    • 71249156207 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150
    • Presented at
    • Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28, 2009.
    • 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28, 2009
    • Higano, C.1    Saad, F.2    Somer, B.3
  • 31
    • 70349926513 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer
    • Abstract 7. Presented at
    • Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Abstract 7. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28,2009.
    • 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28,2009
    • Small, E.1    Demkow, T.2    Gerritsen, W.R.3
  • 33
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
    • TROPIC Investigators This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC
    • De Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147-54. This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 34
    • 70349456786 scopus 로고    scopus 로고
    • A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu
    • This is an extension of the sipuleucel-T platform to another antigen
    • Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937-44. This is an extension of the sipuleucel-T platform to another antigen.
    • (2009) Clin Cancer Res , vol.15 , Issue.18 , pp. 5937-5944
    • Peethambaram, P.P.1    Melisko, M.E.2    Rinn, K.J.3
  • 35
    • 46749085802 scopus 로고    scopus 로고
    • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
    • Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-54.
    • (2008) Lancet , vol.372 , Issue.9633 , pp. 145-154
    • Wood, C.1    Srivastava, P.2    Bukowski, R.3
  • 36
    • 79955846344 scopus 로고    scopus 로고
    • An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: Secondary analysis of a multicenter phase III trial
    • Doehn C, Richter A, Theodor RA, et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase III trial. European Urology Supplements 2006; 5(2);286.
    • (2006) European Urology Supplements , vol.5 , Issue.2 , pp. 286
    • Doehn, C.1    Richter, A.2    Theodor, R.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.